Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
Filter by
-
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal gr...
Read more -
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Major milestone for the GSK and Save the Children partnership and its mission to help save the li...
Read more -
Results announcement for the first quarter 2016
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER)...
Read more -
GSK statement on pneumococcal vaccine pricing
For many years we have been working hard, in partnership with others, to develop vaccines against...
Read more -
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Follows announcement by majority shareholder GSK to expand graduated approach to patents and inte...
Read more -
GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis
GSK announces the start of a phase II study to evaluate the efficacy and safety of an investigati...
Read more -
GSK opens new state of the art respiratory manufacturing facility in Ware, UK
GSK today opens a £56 million state of the art manufacturing facility, creating 150 new jobs in t...
Read more -
GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID
GSK announces a positive opinion recommending marketing authorisation for Strimvelis to treat pat...
Read more -
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
GSK has a deep commitment to improving healthcare by developing innovative new medicines and wide...
Read more -
GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan
GSK announces that the Japanese Ministry of Health, Labour and Welfare has granted approval for N...
Read more -
Sir Andrew Witty to retire from GSK in March 2017
In the publication of its 2015 Annual Report to shareholders, GSK plc today announced that Sir An...
Read more -
GlaxoSmithKline plc (the “Company”) Directorate changes
The Company today announces that Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and H...
Read more -
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma
GSK today announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study.
Read more -
GSK and Miltenyi Biotec establish cell and gene therapy collaboration
Collaboration includes discovery programme for CAR-T cell-based oncology therapies
Read more -
GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels
GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meetin...
Read more -
NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma
GSK today announced publication of results from the ‘LABA’ (long acting beta2-agonist) safety stu...
Read more -
GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
GSK today presented new safety and efficacy data for Nucala® (mepolizumab) from the open-label CO...
Read more -
GSK names winners of 2015 Discovery Fast Track Challenge
Six winning proposals were selected from 378 entries submitted from 21 countries across Europe an...
Read more -
New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)
Patients with SLE are at risk of irreversible organ damage which will accrue over time and is ass...
Read more -
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in B...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
